191 related articles for article (PubMed ID: 8290673)
1. Thioridazine improves affective symptoms in schizophrenic patients.
Dufresne RL; Valentino D; Kass DJ
Psychopharmacol Bull; 1993; 29(2):249-55. PubMed ID: 8290673
[TBL] [Abstract][Full Text] [Related]
2. Depressive symptoms in acute schizophrenic hospitalized patients.
Lerner Y; Moscovich D
J Clin Psychiatry; 1985 Nov; 46(11):483-4. PubMed ID: 4055708
[TBL] [Abstract][Full Text] [Related]
3. Gepirone extended-release treatment of anxious depression: evidence from a retrospective subgroup analysis in patients with major depressive disorder.
Alpert JE; Franznick DA; Hollander SB; Fava M
J Clin Psychiatry; 2004 Aug; 65(8):1069-75. PubMed ID: 15323591
[TBL] [Abstract][Full Text] [Related]
4. Plasma HVA in psychiatric patients: longitudinal studies.
Javaid JI; Sharma RP; Janicak PG; Davis JM
Psychopharmacol Bull; 1990; 26(3):361-5. PubMed ID: 2274637
[TBL] [Abstract][Full Text] [Related]
5. [Antidepressive effect of pyridoxine (vitamin B6) in neuroleptic-treated schizophrenic patients with co-morbid minor depression--preliminary open-label trial].
Shiloh R; Weizman A; Weizer N; Dorfman-Etrog P; Munitz H
Harefuah; 2001 May; 140(5):369-73, 456. PubMed ID: 11419053
[TBL] [Abstract][Full Text] [Related]
6. Empirical evaluation of the factorial structure of clinical symptoms in schizophrenia: effects of typical neuroleptics on the brief psychiatric rating scale.
Harvey PD; Davidson M; White L; Keefe RS; Hirschowitz J; Mohs RC; Davis KL
Biol Psychiatry; 1996 Oct; 40(8):755-60. PubMed ID: 8894068
[TBL] [Abstract][Full Text] [Related]
7. Mesoridazine and thioridazine: clinical effects and blood levels in refractory schizophrenics.
Vital-Herne J; Gerbino L; Kay SR; Katz IR; Opler LA
J Clin Psychiatry; 1986 Jul; 47(7):375-9. PubMed ID: 2873133
[TBL] [Abstract][Full Text] [Related]
8. A 12-week, double-blind, placebo-controlled trial of donepezil as an adjunct to haloperidol for treating cognitive impairments in patients with chronic schizophrenia.
Lee BJ; Lee JG; Kim YH
J Psychopharmacol; 2007 Jun; 21(4):421-7. PubMed ID: 17092979
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of subjective treatment satisfaction with antipsychotics in schizophrenia patients.
Fujikawa M; Togo T; Yoshimi A; Fujita J; Nomoto M; Kamijo A; Amagai T; Uchikado H; Katsuse O; Hosojima H; Sakura Y; Furusho R; Suda A; Yamaguchi T; Hori T; Kamada A; Kondo T; Ito M; Odawara T; Hirayasu Y
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Apr; 32(3):755-60. PubMed ID: 18226436
[TBL] [Abstract][Full Text] [Related]
10. [Cause of mortality in schizophrenic patients: prospective study of years of a cohort of 150 chronic schizophrenic patients].
Bralet MC; Yon V; Loas G; Noisette C
Encephale; 2000; 26(6):32-41. PubMed ID: 11217537
[TBL] [Abstract][Full Text] [Related]
11. Emotional withdrawal, CT abnormalities and drug response in late life depression.
Altamura AC; Bassetti R; Santini A; Frisoni GB; Mundo E
Prog Neuropsychopharmacol Biol Psychiatry; 2004 Mar; 28(2):349-54. PubMed ID: 14751432
[TBL] [Abstract][Full Text] [Related]
12. Multicenter study comparing thioridazine with diazepam and placebo in elderly, nonpsychotic patients with emotional and behavioral disorders.
Stotsky B
Clin Ther; 1984; 6(4):546-59. PubMed ID: 6380725
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics.
Lindenmayer JP; Eerdekens E; Berry SA; Eerdekens M
J Clin Psychiatry; 2004 Aug; 65(8):1084-9. PubMed ID: 15323593
[TBL] [Abstract][Full Text] [Related]
14. [Negative symptoms, depression, anxiety and alexithymia in DSM III-R schizophrenic patients].
Nkam I; Langlois-Thery S; Dollfus S; Petit M
Encephale; 1997; 23(4):267-72. PubMed ID: 9417392
[TBL] [Abstract][Full Text] [Related]
15. Association between multidrug resistance 1 (MDR1) gene polymorphisms and therapeutic response to bromperidol in schizophrenic patients: a preliminary study.
Yasui-Furukori N; Saito M; Nakagami T; Kaneda A; Tateishi T; Kaneko S
Prog Neuropsychopharmacol Biol Psychiatry; 2006 Mar; 30(2):286-91. PubMed ID: 16386826
[TBL] [Abstract][Full Text] [Related]
16. [Alexithymia in negative symptom and non-negative symptom schizophrenia].
Nkam I; Langlois-Thery S; Dollfus S; Petit M
Encephale; 1997; 23(5):358-63. PubMed ID: 9453928
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of quetiapine for depressive symptoms in patients with schizophrenia.
Lee KU; Jeon YW; Lee HK; Jun TY
Hum Psychopharmacol; 2009 Aug; 24(6):447-52. PubMed ID: 19606454
[TBL] [Abstract][Full Text] [Related]
18. Neurocognitive effects of ziprasidone and related factors in patients with chronic schizophrenia undergoing usual care: a 12-month, open-label, flexible-dose, naturalistic observational trial.
Gibel A; Ritsner MS
Clin Neuropharmacol; 2008; 31(4):204-20. PubMed ID: 18670244
[TBL] [Abstract][Full Text] [Related]
19. Schizoaffective disorder: a form of schizophrenia or affective disorder?
Evans JD; Heaton RK; Paulsen JS; McAdams LA; Heaton SC; Jeste DV
J Clin Psychiatry; 1999 Dec; 60(12):874-82. PubMed ID: 10665641
[TBL] [Abstract][Full Text] [Related]
20. The impact of omega-3 fatty acids, vitamins E and C supplementation on treatment outcome and side effects in schizophrenia patients treated with haloperidol: an open-label pilot study.
Sivrioglu EY; Kirli S; Sipahioglu D; Gursoy B; Sarandöl E
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Oct; 31(7):1493-9. PubMed ID: 17688987
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
